Straightforward preparation of enantiopure 3-amino-4,4-dimethylpyrrolidin-2-one and its derivatives
摘要:
An easy access to both enantiomers of 3-amino- and 3-(dimethylamino)-4,4-dimethylpyrrolidin-2-one from rac-pantolactam using (R)-alpha-methylbenzylamine as a chiral auxiliary is described. (C) 2010 Elsevier Ltd. All rights reserved.
The present invention is intended to provide a compound or a pharmacologically acceptable salt thereof which has an excellent inhibitory action on the ATPase activity of a TIP48/TIP49 complex and as such, is useful for the treatment of tumors.
[Solution]
The present invention provides a compound having a structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, and a pharmaceutical composition comprising the compound. In the formula, R1, R2, R3, R4, R5, R6, R7, and W are as defined in the present specification.
本发明旨在提供一种化合物或其药理学上可接受的盐,该化合物或其药理学上可接受的盐对 TIP48/TIP49 复合物的 ATPase 活性具有极佳的抑制作用,因此可用于治疗肿瘤。
[解决方案]
本发明提供了一种具有通式(I)所代表结构的化合物或其药理学上可接受的盐,以及包含该化合物的药物组合物。式中,R1、R2、R3、R4、R5、R6、R7 和 W 如本说明书中所定义。
Azetidine compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
申请人:SANOFI
公开号:US10392366B2
公开(公告)日:2019-08-27
The present disclosure relates to azetidine compounds. The azetidine compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The present disclosure furthermore relates to the use of azetidine compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.